Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit. Amgen’s biosimilar formulation ...

Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The ...

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...

Before Mike White created HBO's hit show "The White Lotus," he penned successes like "School of Rock" and "Chuck & Buck." But some of White's most memorable work yet was perhaps when he became the ...

We recently published a list of the 10 Best Vaccine Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other best ...

In early February, Amgen released financial results for the 4th quarter of 2024, which I was eagerly awaiting. In addition to demonstrating efficacy in the treatment of nasal polyps in Phase 3 ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other best retirement stocks to buy according to hedge funds. After much suspense, the US Federal ...

The FDA has approved AstraZeneca and Amgen's severe asthma hope tezepelumab ... to people with high levels of eosinophils, a type of white blood cell. They include Sanofi/Regeneron's IL-4/IL ...

Mr. Walbert led Horizon, a company that focused on medicines for rare diseases, from its founding in 2008 to acquisition by Amgen in 2023. Mr. Walbert is currently senior advisor, Amgen.